
December 9, 2019
Liu
My research interests include, identification of polysaccharide-based receptor; structure and specificity of a heparan sulfate-based herpes simplex virus 1 receptor; drug targeting; gene therapy.

December 9, 2019
My research interests include, identification of polysaccharide-based receptor; structure and specificity of a heparan sulfate-based herpes simplex virus 1 receptor; drug targeting; gene therapy.

December 5, 2019
I am the Director of the Francis Owen Blood Research Laboratory (FOBRL), the mission of which is to reduce human and animal suffering from bleeding, thrombosis and atherosclerosis by the study of unique, genetically-determined animal models of these diseases. The FOBRL was established in 1960 by Dr. Kenneth M. Brinkhous and has provided work and study opportunities for many undergraduate, M.D., D.V.M. and Ph.D. students, post-doctoral students, and faculty at UNC and from several institutions worldwide.

December 5, 2019
Research Interests My research focus is clinical research in the field of therapeutic apheresis, specifically thrombotic thrombocytopenic purpura (TTP). Although my research started quite small, using data and samples from UNC, it has grown to be incredibly collaborative through a number of professional organizations and relationships throughout the country and internationally. I have evolved my …

December 5, 2019
My lab develops microfluidic models of the blood and lymphatic vasculature for basic science and translational purposes. Specific projects relevant to the Blood Research Center are: 1) Understanding the role of Notch receptor signaling in vascular endothelial adherens junction assembly and stability; 2) A nascent collaboration with Dr. Prabir Roy-Chaudhury at the UNC Kidney center to screen patient plasma in microfluidic models of the vasculature to predict risk of cardiovascular complications in kidney disease.

December 2, 2019
As individuals with sickle cell disease (SCD) are living longer, there is a growing adolescent and young adult population with unique manifestations of SCD that are poorly understand. My research interests are broadly in understanding clinical outcomes in SCD management, characterizing individuals at greater risk for complications and in improving guideline-based care of those with SCD, especially in the diagnosis and management of iron overload. I am joining the non-malignant hematology faculty at UNC and am interested in pursing research in non-malignant hematology. As a member of the BRC, I will have the support and opportunity to continue my research pursuits.